ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial

Core Insights - ClearPoint Neuro, Inc. congratulates its partner Aspen Neuroscience for the successful use of the ClearPoint Neuro Navigation System in the ASPIRO Phase 1/2a clinical trial for Parkinson's Disease patients [1][2] Company Overview - ClearPoint Neuro is a global device, cell, and gene therapy-enabling company that provides precise navigation to the brain and spine, with FDA clearance and CE-mark for its flagship product, the ClearPoint Neuro Navigation System [5] - The company engages with healthcare and research centers globally and partners with innovative pharmaceutical and biotech companies for CNS delivery of therapeutics [5] ASPIRO Trial Details - The ASPIRO trial is an open-label study assessing the safety and tolerability of ANPD001, an autologous dopaminergic neuron cell replacement therapy for moderate to severe Parkinson's Disease [2][10] - The primary endpoint focuses on safety and tolerability, while secondary endpoints include improvements in "on" time, motor symptoms, and quality of life [2] ANPD001 Therapy - ANPD001 is an investigational autologous neuronal replacement therapy that does not require immunosuppressive drugs due to its personalized approach [3] - The therapy involves reprogramming a small sample of the patient's skin cells into induced pluripotent stem cells (iPSCs), which are then differentiated into dopaminergic neuron precursor cells (DANPCs) for transplantation [11][12] Surgical Approach - The transplantation of DANPCs is performed in the putamen using ClearPoint MRI guidance, ensuring minimally invasive delivery with submillimetric accuracy [8][9] - The surgical method was developed by Dr. Paul Larson, a pioneer in MRI-guided stereotactic neurosurgery [8]